SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response.	0.5									

							. ,											
1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Catalyst Pharmaceutical Partners, Inc.								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
WALLACE MILTON J				Catalyst Pharmaceutical Partilers, mc. [CPRX]								X Directo	or		10% Ov	wner		
(Last)	(F	irst)	(Middle)									Officer below)	(give title		Other (s below)	specify		
355 ALHAMBRA CIRCLE					3. [3. Date of Earliest Transaction (Month/Day/Year)												
			10	10/20/2009														
SUITE 1370																		
(Street)					- 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
CORAL														,	iled by On	e Ren	orting Perso	n
GABLES	s ^{Fl}	L	33134													•	n One Repo	
					_									Persor		ic that	n one rrepo	ung
(City)	(5	itate)	(Zip)															
(City)	(5		(210)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date					saction	ction 2A. Deemed 3. 4. Securities Acquired (A) Execution Date, Transaction Disposed Of (D) (Instr. 3, 4						5. Amou Securitie			vnership 1: Direct	7. Nature of Indirect		
			/Day/Ye	ay/Year) if any Code (Instr. 5)				a. 5, 4 and	Beneficial		ally (D) or		Beneficial Ownership					
										Reported ((Instr. 4)					
						Code V Amount (A) or (D)				Price	e Transaction(s) (Instr. 3 and 4)							
		-	Tabla II	Daviva	*****	<u> </u>	wition	٨٥٣		Dia	noood of	or Dom	ficially	Ourmod			I	
			Table II - I (converti			Owned				
1. Title of	4.								8. Price of	9. Numbe	or of	10.	11. Nature					
Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D	Date,	Transa		ction of		Expirat	tion Da	ate	of Securit	ies	Derivative	derivative	е	Ownership	of Indirect
Security (Instr. 3)	or Exercise Price of		if any (Month/Day/Year		Code (Instr r) 8)		e (Instr. Derivative Securities		(Month	(Month/Day/Year) Underlying Derivative Sec				Security (Instr. 5)	Securities Beneficia		Form: Direct (D)	Beneficial Ownershi
	Derivative Security					Acquired (Instr. 3 and 4 (A) or Disposed				nd 4)		Owned Following	D	or Indirect (I) (Instr. 4)				
	coounty											Reported Transaction(s)		(.) (1			
						of (D) (Instr. 3, 4 and 5)						(instr. 4)	ion(s)					
				F								1	Amount	1				
													or Number					
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	of Shares					
				1. 1		1					1	1		1	1			

10/20/2009

Explanation of Responses:

\$<mark>0.9</mark>

Options to purchase

. common

stock

/s/ Milton J. Wallace

Common

Stock

10/20/2014

<u>10/22/2009</u> Date

51,000

D

** Signature of Reporting Person

30,000

\$<mark>0</mark>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

10/20/2009

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Α

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

30.000